Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells

Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype, and it exhibits resistance to common breast cancer therapies. Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and its ligand, PD-L1, have been approved to treat various cancers. However, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Saleh, Reem, Toor, Salman M, Khalaf, Sarah, Elkord, Eyad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963740/
https://www.ncbi.nlm.nih.gov/pubmed/31614877
http://dx.doi.org/10.3390/vaccines7040149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963740/
https://www.ncbi.nlm.nih.gov/pubmed/31614877
http://dx.doi.org/10.3390/vaccines7040149

Ejemplares similares